Tel Aviv University

Moshe Portnoy

Daniel Offen

Irit Gil-Ad

Hagit Eldar-Finkelman

Gerardo Zelmar Lederkremer

Javier Ganz

Julia Leitman

Avraham Weizman

Hagit Eiger

Compounds represented by Formula I are disclosed herein,  wherein R, Ra and R-Rare as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.

PERK inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins

Compounds represented by Formula I are disclosed herein, wherein R, Ra and R-Rare as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.

Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins

The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders.

Psychotropic agents having glutamate NMDA activity

Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.

Growing community of inventors

Ramat-Hasharon, Israel

Moshe Portnoy